Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

talk with your doctor or pharmacist Ingrezza is a brand-name medication that comes in an oral capsule and an oral sprinkle capsule. It’s prescribed for certain movement disorders. If you have ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said it presented positive data from Phase 3 KINECT-HD study evaluating Ingrezza capsule in adults with Huntington's disease at the ...

Now Neurocrine Bioscience, with Ingrezza and elagolix not far behind it, could become a significant mid-size company within just a few years. Andrew McConaghie 11 April, 2017 ...

The company is best known for its drug, Ingrezza. Ingrezza treats tardive dyskinesia and chorea associated with Huntington's disease. Both are movement disorders. But in the fourth quarter ...

The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital ...

Neurocrine (NBIX) Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA capsules in adults with Huntington ...